International Journal of Applied Pharmaceutics

ISSN- 0975-7058 Vol 16, Issue 2, 2024

Original Article

DEVELOPMENT AND VALIDATION OF AN LC-MS/MS METHOD FOR THE DETERMINATION OF TENOFOVIR AND EMTRICITABINE

INDIRA PRIYADARSHINI, AKILA DEVI D.*

Department of Pharmaceutics, Vels Institute of Science, Technology and Advanced Studies, Chennai-600117, Tamil Nadu, India
***Corresponding author: Akila Devi D.; *Email: darshinipharma@gmail.com**

Received: 04 Aug 2023, Revised and Accepted: 28 Dec 2023

ABSTRACT

Objective: Therapeutic drug monitoring of tenofovir and emtricitabine, two commonly used antiretroviral drugs, is important to maximize effectiveness while minimizing side effects.

Materials: A Liquid Chromatography-Mass spectrometry (LC-MS/MS) method was developed to quantify tenofovir and emtricitabine in human plasma samples. The method involves a simple solid phase extraction procedure followed by liquid chromatography separation using a Penta Fluoro Phenyl (PFP) column with a Phenomenex C18 column and a mobile phase of ammonium formate, acetonitrile, and methanol, achieving separation in under 4 min.

Results: The method showed good accuracy, low limits of quantification, adequate recovery, minimal matrix effects, and specificity. Analyte stability under multiple storage conditions was demonstrated.

Conclusion: The validated LC-MS/MS method provides a reliable tool for therapeutic drug monitoring and pharmacokinetic studies of anti-Human Immuno-deficiency Virus (HIV) regimens. The assay can be applied to large populations, especially in resource-poor settings, to help individualize dosing and improve clinical outcomes while reducing toxicity.

Keywords: Liquid chromatography, Mass spectroscopy, Pharmacokinetics, Tenofovir, Emtricitabine, Validation

DOI: https://dx.doi.org/10.22159/ijap.2024v16i2.49667 Journal homepage: https://innovareacademics.in/journals/index.php/ijap

INTRODUCTION

Liquid Chromatography-Mass spectrometry (LC-MS) coupled with a Turbo spray interface (TSI) provides a sensitive and powerful technique [1, 2]. LC separates mixtures into components, while MS identifies components with high specificity and sensitivity. The coupled technique can analyze biochemical, organic, and inorganic compounds in complex samples [3, 4].

Tenofovir and emtricitabine inhibit Human Immuno-deficiency Virus (HIV) reverse transcriptase and lower the amount of HIV in the body. They are administered together as part of highly active antiretroviral therapy (HAART) [5, 6]. A bioanalytical method is needed to determine drug concentrations in biological fluids like plasma for purposes of therapeutic drug monitoring and pharmacokinetic studies. LC-MS/MS method provides a significantly faster run time compared to other bioanalytical methods, allowing high-throughput analysis for therapeutic drug monitoring and pharmacokinetic studies. Moreover, the LC-MS/MS technique offers high sensitivity and specificity advantageous for analysis in biological matrices. The proposed method once validated, provides an efficient tool to optimize anti-retroviral therapy through individualized dosing for large patient populations, especially in resource-limited settings [7, 8]. Method development and validation ensure a reliable technique under given laboratory conditions using available resources. This includes demonstrating that the technique is reproducible and fit for its intended use in analyzing drug levels in biological matrices [9, 10]. The main objective of this study is to develop and validate an efficient LC-MS/MS method for the simultaneous quantification of tenofovir and emtricitabine in human plasma samples to optimize antiretroviral therapy.

MATERIALS AND METHODS

Materials

The analytes, tenofovir and emtricitabine, and their internal standards (tenofovir-d7 and emtricitabine-d2) were procured from Clear synth Ltd, Hyderabad. Methanol and acetonitrile are obtained from Thermo Fischer Scientific, Hyderabad, while ammonium formate, formic acid, and ammonia solution are obtained from Merck Specialities Ltd, Kakinada.

Blank plasma

K2 Ethylene Diamine Tetra-acetic acid (EDTA) human blank plasma was sourced from Doctor's Pathological Lab in Hyderabad. This plasma was used for method development, validation, and analysis. This technique was utilized to generate calibration standards and quality control samples. The plasma was collected from healthy, non-smoking volunteers who provided informed consent for use for research purposes. Blood samples were collected in K2 EDTA vacutainers from the volunteers [11].

Instrumentation

The study utilized the following instruments for the analysis. An analytical balance model, CP225D from Sartorius, was used. A centrifuge model SW12R from Firlabo, France, was employed. Deep freezers at-86 °C and-20 °C of the VIP series from Sanyo, USA, were used to store samples. A High-Performance Liquid Chromatography (HPLC) system from Shimadzu, Japan, comprising LC-20 AD pumps, DGU-20 A3 degasser, CTO-ASVP column oven, and SIL HTC autosampler was utilized. A microbalance model CP2P from Sartorius, Germany, was used. Micropipettes of 5-50 µl and 100-1000 µL from Brand, Germany, were employed. An API-4000 mass spectrometer with Turbo ion spray interface in negative ionization mode from MDA, Sciex, Canada, was used. A Turbo Vap LV nitrogen evaporator from Caliper Life Sciences, USA, was used. An Orion star pH meter from Thermo Electron Corporation, USA, was employed. A SpeeDisk-48 solid phase extraction unit from Orochem Technologies, USA, was used. A Powersonic 510 ultrasonic bath from Hwashin Technologies, Korea, and a Spinix vortex from Tarsons, India, were utilized. Purified water was obtained from water purification units, including the Elix 10 and Milli-Q gradient A10 from Millipore, USA. Data acquisition and processing on the LC-MS/MS instrument were performed using Analyst software version 1.5.1.

Chromatographic conditions

The chromatographic conditions were optimized through a trial and

error or scouting approach. Various parameters were varied and tested to determine the optimal conditions for best performance [12, 13]. The mobile phase consisted of 5 mmol ammonium formate-acetonitrile-methanol 60:25:15 (v/v/v). A Kinetex PFP, 50 X 4.6 mm, 5µm (Phenomenex) column was used. The flow rate was 1.0 ml/min with an injection volume of 10 µl. The column oven temperature was 35±1 °C, and the autosampler temperature was 5±1 °C. The retention times were tenofovir: 1.53 min., emtricitabine: 2.14 min., tenofovir-d7: 1.54 min internal standard (ISTD), and emtricitabine-d2: 2.14 min (ISTD) and the run time was 3.2 min with a splitness of 50:50.

Mass spectrometric conditions

For mass spectrometric detection, a turbo ion spray interface operated in positive ion mode was used [14, 15]. The multiple reaction monitoring (MRM) transitions monitored were 288/176.1 for tenofovir and 295.2/183.1 for tenofovir-d7, which served as the internal standard. Emtricitabine had a transition of 248.2/130.1, while emtricitabine-d2, the internal standard, was monitored at 250.1/130.2.

The dwell time was set to 300 ms for each transition. Quadrupoles 1 and 3 were operated at unit resolution. The gas/turbo ion spray source parameters were optimized as follows. Nitrogen was used as the ion source gas 1 and was set at 35 psi to aid in analyte spray formation [16]. Nitrogen was also used as ion source gas 2 at 45 psi to stabilize the ion spray. A curtain gas flow of 30 psi of nitrogen was used to improve ion transmission into the mass spectrometer. The collision gas was set at 10 psi of nitrogen for collision-induced dissociation. The ion spray voltage was set to 5000 V to produce maximally charged droplets. The source temperature was maintained at 500 °C to assist desolvation of ions and droplets. The interface heater setting was turned on to further aid the desolvation of ions entering the mass spectrometer [17]. The mass spectrometric parameters were optimized to achieve maximum sensitivity. The declustering potential was 45V for tenofovir and tenofovir-d7 while it was 52V for emtricitabine and emtricitabine-d2. An entrance potential of 10V was applied for all analytes. A collision energy of 29V was used for tenofovir and tenofovir-d7 while 32V was used for emtricitabine and emtricitabine-d2. The collision cell exit potential was 13V for tenofovir and tenofovir-d7 and 20V for emtricitabine and emtricitabine-d2.

Stock solutions and calibration standards

Individual stock solutions of 1 mg/ml tenofovir and 1 mg/ml emtricitabine were prepared in methanol to quantify the drugs in human plasma using LC-MS/MS [18, 19]. Serial dilutions of these stock solutions were performed to obtain calibration standards and quality control samples. Separately, internal standard stock solutions of 2 mg/ml tenofovir-d7 and 2 mg/ml emtricitabine-d2 were diluted to achieve a 500 µg/ml working concentration of each internal standard [20]. The stock solutions were stored at 2-8 °C and found to be stable for 22 d [21].

Calibration curves ranging from 5 to 500 ng/ml for tenofovir and 8 to 4000 ng/ml for emtricitabine were made. Quality control plasma samples were also prepared to standardize the method developed. The tenofovir concentrations used were 5 ng/ml, 15 ng/ml, 211 ng/ml, 382 ng/ml, and 1000 ng/ml, corresponding to emtricitabine concentrations of 8 ng/ml, 24 ng/ml, 1675 ng/ml, 3046 ng/ml and 8000 ng/ml representing quality control levels of the lowest limit of quantification quality control (LLOQ), low-quality control (LQC), medium quality control (MQC), high-quality control (HQC) and dilution quality control (DQC) respectively.

Desired drug levels in plasma were achieved by spiking with 1% of the working standard dilutions. Long-term stability quality control samples were prepared in pooled plasma and stored at-70 °C. For sample preparation, 400 µL of plasma was mixed with 100 µL of the 500 µg/ml internal standard solution. Then 0.4 ml of 0.2% formic acid was added and loaded onto preconditioned Phenomenex Strata-X solid phase extraction cartridges. The cartridges were washed and eluted with 1 ml of 2% ammoniated methanol. The eluate was dried under nitrogen, reconstituted in 400 µL mobile phase, and 10 µL injected into the LC-MS/MS system [22].

Method validation

System suitability and repeatability assessment

To assess that the LC-MS/MS system and method were functioning properly, 2 injections of a low-concentration calibration standard and 6 injections of a high-concentration calibration standard were performed for tenofovir and emtricitabine [23]. The low concentration standard was injected to inspect the peak shapes. The coefficient of variation (%CV) of the area ratios from the six high-concentration standard injections should be less than 4% according to guidelines [21].

Carryover and cleaning validation

To evaluate the autosampler performance in terms of carryover, extracted blank samples, high-standard samples, and low-standard samples were injected. The carryover should not be more than 20% and 5% at the retention times of the analytes and internal standards, respectively [24].

Selectivity, sensitivity, and suitability of the assay

The ability of the method to accurately measure analyte concentrations in the presence of endogenous plasma components and exogenous interfering substances was evaluated. Selectivity was assessed by analyzing 8 different lots of drug-free human plasma along with 2 lots each of hemolyzed plasma and lipemic plasma that were processed using the sample preparation method [3]. The effect of co-administered medications was studied by spiking acetaminophen, ibuprofen, ranitidine, and ondansetron into analyte-free plasma at concentrations equivalent to their reported maximum plasma levels found in patients [21]. Any interfering peaks at the retention times of tenofovir, emtricitabine and their internal standards were monitored to determine the selectivity of the method for the intended purpose in real patient samples.

Evaluation of matrix effects

Matrix effects should be evaluated for mass spectrometry-based methods to assess signal suppression or enhancement due to the ionization of analytes in biological matrices. To determine if the method was free from matrix effects, the post-extraction responses of tenofovir and emtricitabine in plasma samples from 10 different donors (including 2 each of hemolyzed and lipemic samples) were compared to the responses in aqueous solutions [25]. Matrix effects were determined at the low and high-quality control levels by calculating the matrix factor for the analyte and corresponding internal standard. Then, the matrix factor of the analyte was normalized to the internal standard matrix factor to obtain the internal standard normalized matrix factor. A value of 1 indicates no matrix effects, while the limits for the normalized matrix factor are 0.85 to 1.15 [26].

Method linearity

Three calibration curves were analyzed to evaluate linearity. The peak area ratios of the analyte to standard internal response were plotted on the y-axis against concentration on the x-axis [14, 27].

Extraction efficiency (Recovery)

Consistent and comparable extraction recovery during sample preparation was necessary for precise and accurate quantitative results. The relative recovery of tenofovir and emtricitabine was evaluated at three concentration levels (low, medium, and high-quality control samples) by comparing the response of post-extraction spiked plasma samples to pre-extraction spiked plasma samples (n = 6) [14]. Absolute recovery was also determined by comparing the response of extracted plasma samples to standard aqueous solutions [28].

Accuracy and precision

The accuracy and precision of the method over a complete run size were evaluated to demonstrate the reproducibility and consistency of the method [29]. A total of 50 replicates each of low, medium, and high-quality control samples were prepared and quantified against

freshly prepared calibration curves. The quality control samples were injected in ascending order of concentration from low to high [30].

Stability evaluation

The stability of tenofovir and emtricitabine was assessed under various conditions: short-term bench-top stability at room temperature, freeze-thaw stability after 5 cycles, autosampler stability, dried extract stability, and long-term stability at-70 °C [31].

RESULTS AND DISCUSSION

Method development

To obtain precise and reliable quantification results, it is vital to fine-tune the chromatographic process variables, sample extraction process, and mass spectrometric parameters with equal importance. These different aspects must be tuned and developed in harmony for the best overall performance of the analytical method [32].

Optimization of LC-MS/MS conditions

The analytes (tenofovir, emtricitabine, and their internal standards) were individually infused into the mass spectrometer to optimize the MS conditions for better sensitivity [33]. Initially, a Q1 scan was performed by optimizing the Declustering Potential (DP) and Entrance Potential (EP) to select the parent ion. This was followed by an MS/MS scan to optimize the Collison Energy (CE) and Collison Cell Exit Potential (CXP) to select product ions. In optimizing the mass spectrometric parameters for quantification, the $[M^+H]^+$ precursor ions observed in the mass spectrum, along with their reproducible fragment ions, were selected for MRM quantification. Unit resolution mode with 300 ms dwell time was employed for every transition. Different stationary phases like C18 and C8 were evaluated. The Phenomenex PFP column gave a better peak shape, resolution, and required sensitivity. A moderate-strength buffer of 5 mmol ammonium formate provided a more signal-to-noise ratio. The total run time was 3.2 min. The product ion spectra of analytes and internal standards are shown in fig. 1.



Fig. 1: Product ion spectra of a. Tenofovir b. Emtricitabine, c. tenofovir-d7–ISTD and d. emtricitabine-d2-ISTD

Sample preparation method development

Both liquid-liquid extraction and solid-phase extraction techniques were evaluated for preparing plasma samples. After considering various methods for solid phase extraction, the Phenomenex Strata-X cartridges were chosen as the preferred option due to their ability to provide high and uniform extraction recoveries, minimal matrix effect, and clear sample extracts. Although washing the cartridges with 5% methanol initially provided chromatograms with clean peaks, the recovery rates for emtricitabine were observed to be low. Washing the cartridges with 0.1% formic acid solution improved the recovery of emtricitabine. The extraction procedure was carefully optimized and adjusted to obtain similar recoveries for both the analytes (tenofovir and emtricitabine) and their corresponding internal standards (tenofovir-d7 and emtricitabine-d2). The comparable recoveries for analytes and internal standards, along with acceptable normalized response factors of the internal standards, led to a stable and reproducible quantification method [23].

Method validation

System suitability and repeatability assessment

The actual % CV values found for the area ratios ranged from 0.42% to 2.38% across the entire method validation, demonstrating that the LC-MS/MS system and method yielded repeatable and reproducible results with good precision [21, 34]. This indicated that the system and analytical method were suitable for the intended purpose. The results of the system suitability and repeatability assessment are shown in table 1.

Table 1: Results of system suitability and repeatability assessment

S. No.	System suitability		
	Parameter	**Acceptance criteria**	**% CV observed**
01	Retention time	±2.0%	0.61%
02	Capacity factor (k')	1.5-20	10.23
03	Tailing factor (T)	0.8-1.5	1.02
Repeatability			
04	Intra-day precision	≤15% at LLOQ, ≤15% at LQC and ≤15% at HQC	0.42% to 2.12%
05	Inter-day precision	≤15% at LLOQ, ≤15% at LQC, and ≤15% at HQC	0.89% to 2.38%

Carryover and cleaning validation

The results in table 2 show that the carryover is not observed as the peak area in blanks after the Upper Limit of quantification (ULOQ) samples was<20% of LLOQ, indicating good autosampler performance. No interfering peaks were observed in blank water, methanol, or plasma washes, demonstrating the adequacy of the glassware cleaning procedure used [7].

Table 2: Results of carry-over, cleaning validation, selectivity and sensitivity

S. No.	Parameter	Results
01	Carryover assessment	Peak area of carryover in blank after ULOQ<20% of LLOQ
Glassware cleaning validation		
02	Blank water wash	No peaks>20% of LLOQ
03	Blank methanol wash	No peaks>20% of LLOQ
04	Blank plasma wash	No peaks>20% of LLOQ
05	Selectivity	Interference at LLOQ retention time<20% of LLOQ response
Sensitivity		
06	Limit of Detection (LOD)	Tenofovir 0.4 ng/ml Emtricitabine 0.2 ng/ml
07	Lower Limit of Quantification (LLOQ)	Tenofovir 1 ng/ml Emtricitabine 0.5 ng/ml

Selectivity, sensitivity, and suitability of the assay

The interference observed in the blank plasma lots was compared to the mean response of processed samples at LLOQ. The precision and accuracy at the LLOQ level were found to be 10.3% and 109.7% for tenofovir and 8.9% and 102.8% for emtricitabine, respectively. Assay suitability was also assessed, and no cross-talk was observed between the analytes and internal standards, demonstrating the specificity of the method [30].

Evaluation of matrix effect

Matrix factor values close to 1 indicate little matrix effect. The average matrix factor values for tenofovir and emtricitabine were close to 1, ranging from 0.992 to 0.975 and 0.946 to 0.972, respectively (results shown in table 3). This suggests a minimal matrix effect. The %CV (coefficient of variation) values were all below 5%, meeting the typical acceptance criteria for matrix effect evaluation. This indicates good precision and reproducibility in the matrix effect assessment. The matrix factor values were determined for various plasma batches, including hemolytic and lipemic samples. The fact that the matrix factor was consistent across different plasma types indicates the robustness of the method and its suitability for real patient samples. Standard deviation and % CV were slightly higher for HQC samples compared to LQC samples. This is not unexpected as the matrix effect and ion suppression tend to increase at higher analyte concentrations [27].

Method linearity

The calibration curves were linear over the range of 5-500 ng/ml for tenofovir and 8-4000 ng/ml for emtricitabine. The slope values were consistent, and correlation coefficients were ≥0.99. The mean measured concentrations of the calibration standards met the acceptance criteria of accuracy (±15%) and precision (≤15%). Table 4 shows the mean back-calculated concentrations of the calibration standards for tenofovir and emtricitabine.

Extraction efficiency (recovery)

The mean recovery for tenofovir at LQC, MQC, and HQC levels was 83%, 81%, and 84%, respectively, in absolute terms and 83%, 85%,

and 81%, in relative terms. For emtricitabine, the mean recovery at LQC, MQC, and HQC levels was 83%, 80%, and 82% in absolute terms, and 86%, 86%, and 83% in relative terms. The mean recovery of tenofovir-d7 (internal standard) at the MQC level was 85%, while for emtricitabine-d2 (internal standard), it was 84% and 83%, respectively. The recovery values were within acceptable limits, indicating that the extraction method yielded consistent and reproducible recoveries [35].

Table 3: Matrix effect data results

Blank plasma lots	Internal standard normalised matrix factor (ISNMF)			
	Tenofovir		Emtricitabine	
	LQC	HQC	LQC	HQC
Sample-1	0.98	0.95	0.92	1.03
Sample-2	0.97	0.98	0.95	1.06
Sample-3	0.97	0.95	0.91	0.93
Sample-4	0.96	0.94	0.97	0.99
Sample-5	1.03	1.01	0.98	0.99
Sample-6	1.02	1.07	0.96	0.98
Sample-7[a]	1.01	1.02	0.97	1.01
Sample-8[a]	1.02	1.03	0.95	1.05
Sample-9[b]	0.97	0.93	0.95	0.93
Sample-10[b]	0.98	0.96	0.93	0.95
Average	0.992	0.975	0.946	0.972
Standard Deviation	0.0186	0.0347	0.0216	0.0377
% Coefficient of variance	1.9	3.6	2.3	3.9

a-Hemolytic samples, b-Lipemic samples

Table 4: Summary of calibration standards

Tenofovir				Emtricitabine			
Nominal conc (ng/ml)	Mean conc found (ng/ml)	% Accuracy	% Relative error	Nominal conc (ng/ml)	Mean conc found (ng/ml)	% Accuracy	% Relative error
5	4.9	98.0	2.0	8	7.1	88.8	11.3
10	9.5	95.0	5.0	16	15.2	95.0	5.0
25	24.5	98.0	2.0	50	48.9	97.8	2.2
50	49.8	99.6	0.4	250	248.1	99.2	0.8
100	99.7	99.7	0.3	800	752.4	94.1	6.0
200	202.1	101.1	1.1	1600	1564	97.8	2.3
400	401.2	100.3	0.3	3201	3100	96.8	3.2
500	499.5	99.9	0.1	4000	3955	98.9	1.1

Accuracy and precision

The accuracy for the entire run size batch ranged from 89.9% to 105.7%, while the precision was less than 11.5% for both tenofovir and emtricitabine. For tenofovir, the intra-batch accuracy at LLOQ, LQC, MQC, and HQC levels was 98.0%, 93.1%, 95.6%, and 100.1%, respectively, with %CV ranging from 3.7%-11.0%. The inter-batch accuracy for tenofovir was 96.1% at LLOQ, 92.3% at LQC, 97.2% at MQC, and 98.1% at HQC level with % CV between 4.1%-9.9%. For emtricitabine, the intra-batch accuracy was 97.4% at LLOQ, 94.0% at LQC, 99.5% at MQC, and 96.1% at HQC level with % CV between 2.8%-6.6%. The inter-batch accuracy for emtricitabine was 99.0% at LLOQ, 98.2% at LQC, 95.0% at MQC, and 101.0% at HQC level, with %CV ranging from 2.8%-6.5%. This indicated that the method yielded accurate and precise results over a full run size, establishing its reliability for batch analysis of patient samples [32].

The accuracy and precision results obtained from dilution integrity experiments at 1:2 and 1:4 dilutions were also within acceptable limits. The blank plasma chromatograms are shown in fig. 2, while the chromatograms of the analytes at LLOQC and HQC levels are shown in fig. 3 and 4, respectively.



Fig. 2: Blank plasma chromatograms of (a) tenofovir, (b) tenofovir-d7, (c) emtricitabine and (d) emtricitabine-d2



Fig. 3: Chromatograms of (a) tenofovir, (b) tenofovir-d7, (c) emtricitabine and (d) emtricitabine-d2 at LLOQC level



Fig. 4: Chromatograms of (a) tenofovir, (b) tenofovir-d7, (c) emtricitabine and (d) emtricitabine-d2 at HQC level

Stability evaluation

As shown in fig. 5, the tenofovir and emtricitabine stock solutions and working dilutions were steady for 21 d when stored at 2-8 °C. The % mean stability of the analytes ranged from 92.2% to 107.1%. Stability samples at low and high-quality control concentrations were analyzed using a freshly prepared calibration curve. Tenofovir and emtricitabine were found to be stable in human plasma for approximately 16 h at room temperature and after undergoing 5 complete freeze-thaw cycles. The established autosampler stability time (after sample preparation but before injection) was 41 h for tenofovir and emtricitabine, while the dried extract stability (after reconstitution of dried extracts) was 52 h.

The analytes were stable in whole blood for 2.5 h. Long-term stability was evaluated by storing prepared plasma samples at -70 °C, and tenofovir and emtricitabine were found to be stable for at least 32 d under these conditions.



Fig. 5: Stability conditions and results

CONCLUSION

A faster and more sensitive LC-MS/MS method was developed for quantifying tenofovir and emtricitabine in human plasma using positive electrospray ionization. The method was validated according to Food and Drug Administration (FDA), Brazilian Health Regulatory Agency, and European Medical Agency guidelines and has a shorter run time of 3.2 min. MRM analysis with optimized MS/MS conditions was used, and solid phase extraction and a Phenomenex Kinetex PFP column were used for separation. No significant interference was observed in blank plasma samples. Thus, this method can be used as a reliable and efficient tool for therapeutic drug monitoring and pharmacokinetic studies of antiretroviral therapy.

ACKNOWLEDGMENT

The authors would like to thank Dr. P. Nagaraju and Mr. Prakash Nathaniel Kumar Sarella for their valuable time and support in carrying out this work.

AUTHORS CONTRIBUTIONS

All authors are contributed equally.

CONFLICT OF INTERESTS

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

1. Kauhanen D, Sysi-Aho M, Koistinen KM, Laaksonen R, Sinisalo J, Ekroos K. Development and validation of a high-throughput LC–MS/MS assay for routine measurement of molecular ceramides. Anal Bioanal Chem. 2016;408(13):3475-83. doi: 10.1007/s00216-016-9425-z, PMID 26922344.
2. Rackowska E, Bobrowska Korczak B, Giebułtowicz J. Development and validation of a rapid LC–MS/MS method for determination of methylated nucleosides and nucleobases in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1128:121775. doi: 10.1016/j.jchromb.2019.121775, PMID 31493699.
3. Lucatello L, Cagnardi P, Capolongo F, Ferraresi C, Bernardi F, Montesissa C. Development and validation of an LC–MS/MS/MS method for the quantification of fluoroquinolones in several matrices from treated turkeys. Food Control. 2015;48:2-11. doi: 10.1016/j.foodcont.2014.04.011.
4. Eryavuz Onmaz DE, Abusoglu S, Onmaz M, Yerlikaya FH, Unlu A. Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1176:122768. doi: 10.1016/j.jchromb.2021.122768, PMID 34052564.
5. Kromdijk W, Pereira SA, Rosing H, Mulder JW, Beijnen JH, Huitema ADR. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;919-920:43-51. doi: 10.1016/j.jchromb.2013.01.005, PMID 23411018.
6. Paliwal N, Jain P, Dubey N, Sharma S, Khurana S, Kumar Paliwal S. A liquid chromatography tandem mass spectrometry based regulatory compliant method for the determination of tenofovir in human serum. Drug Res. 2014;64(6):306-12. doi: 10.1055/s-0033-1361090, PMID 24310362.
7. Beer B, Schubert B, Oberguggenberger A, Meraner V, Hubalek M, Oberacher H. Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study. Anal Bioanal Chem. 2010;398(4):1791-800. doi: 10.1007/s00216-010-4075-z, PMID 20730580.
8. Bodempudi SB, Rupakula RCB, Reddy KS. Development and validation of RP-chiral HPLC method for quantification of (s)-isomer in tenofovir disoproxil fumarate. Int J Curr Pharm Sci. 2017 Nov 14;9(6):31. doi: 10.22159/ijcpr.2017v9i6.23425.
9. Mistri HN, Jangid AG, Pudage A, Shrivastav P. HPLC–ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864(1-2):137-48. doi: 10.1016/j.jchromb.2008.02.004, PMID 18313371.
10. Attia M KA, Madkour AW, Almrasy AA, Abdelfatah AM. Determination of toltrazuril in presence of complete alkaline degradation product by RP-HPLC and TLC-densitometric methods. Int J Pharm Pharm Sci. 2022 May 1;49–56.
11. Goswami D, Kumar A, Khuroo AH, Monif T, Gurule S, Thudi NR. Liquid chromatographic tandem mass spectrometric validated method for pharmacokinetic estimation of flecainide in human plasma. Clin Res Regul Aff. 2009;26(1-2):24-36. doi: 10.1080/10601330902919797.
12. Wang X, Qi W, Zhao X, Lu T, Wang X, Zheng L. Determination of four phenolic endocrine disruptors in environmental water samples by high-performance liquid chromatography-fluorescence detection using dispersive liquid-liquid microextraction coupled with derivatization. Se Pu. 2014;32(6):623-8. doi: 10.3724/sp.j.1123.2014.02012, PMID 25269261.
13. Mina SA, El-Maksoud AMA, Mohammed HS, Fouad MA. Study of the anti-hyperlipidemic effect of the combined administration of three natural extracts in a poloxamer-407 hyperlipidemic model and their LC-ESI-MS/MS2 and HPLC profiling. Int J Pharm Pharm Sci. 2020 Jul 25:29-35. doi: 10.22159/ijpps.2020v12i9.38385.

14. Zeng M, Zhang J, Yang Y, Jin Y, Xiao W, Wang Z. An automated dual-gradient liquid chromatography–MS/MS method for the simultaneous determination of ferulic acid, ligustrazine and ligustilide in rat plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2014;88:354-63. doi: 10.1016/j.jpba.2013.08.038, PMID 24140450.
15. Babu C, Devanna N, Reddy KVS. Validated gradient stability indicating RP-HPLC method for the simultaneous quantification of 11 related substances in the combined dosage forms of lamivudine and tenofovir disopeoxil fumarate. Int J App Pharm. 2017 Jul 13;9(4):61. doi: 10.22159/ijap.2017v9i4.19001.
16. Girault J, Fourtillan JB. Quantitative measurement of clonidine in human plasma by combined gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 1988;17(6):443-8. doi: 10.1002/bms.1200170605, PMID 3240372.
17. Christianson CD, Laine DF, Zimmer JS, Johnson CJ, Sheaff CN, Carpenter A. Development and validation of an HPLC–MS/MS method for the analysis of dexamethasone from pig synovial fluid using dried matrix spotting. Bioanalysis. 2010;2(11):1829-37. doi: 10.4155/bio.10.137, PMID 21083491.
18. Jain DS, Subbaiah G, Sanyal M, Shrivastav P. A high throughput and selective method for the estimation of valproic acid an antiepileptic drug in human plasma by tandem LC–MS/MS. Talanta. 2007;72(1):80-8. doi: 10.1016/j.talanta.2006.09.033, PMID 19071585.
19. UH, Akm P. Development and validation of stability indicating simultaneous UV-spectrophotometric method for determination of emtricitabine, tenofovir disoproxil fumarate, cobicistat, and elvitegravir in pure and pharmaceutical dosage form. Asian J Pharm Clin Res. 2018 Apr 1;11(4):177. doi: 10.22159/ajpcr.2018.v11i4.22897.
20. Patel DP, Sharma P, Sanyal M, Singhal P, Shrivastav PS. UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers. Biomed Chromatogr. 2013;27(8):974-86. doi: 10.1002/bmc.2889, PMID 23483571.
21. Nagaraju P, Kodali B, Datla PV, Kovvasu SP. LC-MS/MS quantification of tramadol and gabapentin utilizing solid phase extraction. Int J Anal Chem. 2018. doi: 10.1155/2018/1605950, PMID 30510578.
22. Huang MQ, Kang L, Wang W, Skee D, Chen M, Lin ZJ. UPLC-MS/MS assay for the simultaneous determination of ethinyl estradiol, norgestimate and 17-desacetyl norgestimate at low pg/ml in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1017-1018:1-9. doi: 10.1016/j.jchromb.2016.01.054, PMID 26930373.
23. Kuhn J, Knabbe C. Fully validated method for rapid and simultaneous measurement of six antiepileptic drugs in serum and plasma using ultra-performance liquid chromatography–electrospray ionization tandem mass spectrometry. Talanta. 2013;110:71-80. doi: 10.1016/j.talanta.2013.02.010, PMID 23618178.
24. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Ohrman I. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783(2):335-47. doi: 10.1016/s1570-0232(02)00768-7, PMID 12482476.
25. Mazzarino M, Torre X, Botre F. Comparison between reverse phase and hydrophilic interaction liquid chromatography techniques in doping analysis: a case study on phenolalkylamines. In: Recent Adv Doping Anal; 2011. p. 19.
26. Vancea S, Gall Z, Donath Nagy G, Borka Balas R. Rapid LC–MS/MS method for determination of drotaverine in a bioequivalence study. J Pharm Biomed Anal. 2014;98:417-23. doi: 10.1016/j.jpba.2014.06.029, PMID 25005892.
27. Cheng C, Liu S, Xiao D, Hollembaek J, Yao L, Lin J. LC–MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2831-8. doi: 10.1016/j.jchromb.2010.08.037, PMID 20850394.
28. Zhu Z, Neirinck L. High-performance liquid chromatographic method for the determination of gabapentin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 5;779(2):307-12. doi: 10.1016/s1570-0232(02)00399-9, PMID 12361744.
29. Rago B, Fu C. Development of a high-throughput ultra-performance liquidchromatography–mass spectrometry assay to profile 18 eicosanoids as exploratory biomarkers for atherosclerotic diseases. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;936:25-32. doi: 10.1016/j.jchromb.2013.08.001, PMID 23973531.
30. Pappula N, Kodali B, Datla PV. Selective and rapid determination of tadalafil and finasteride using solid phase extraction by high-performance liquid chromatography and tandem mass spectrometry. J Pharm Biomed Anal. 2018;152:215-23. doi: 10.1016/j.jpba.2018.01.020, PMID 29427880.
31. Gonzalez Hernandez I, Ruiz Olmedo MI, Cardenas G, Jung Cook H. A simple LC-MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis. Biomed Chromatogr. 2012;26(2):267-72. doi: 10.1002/bmc.1659, PMID 21721022.
32. Samanidou VF, Nikolaidou KI, Papadoyannis IN. Development and validation of an HPLC confirmatory method for the determination of seven tetracycline antibiotics residues in milk according to the European Union Decision 2002/657/EC. J Sep Sci. 2007;30(15):2430-9. doi: 10.1002/jssc.200700057, PMID 17628871.
33. Wei F, Liu X, Liao X, Shi L, Zhang S, Lu J. Simultaneous determination of 19 mycotoxins in lotus seed using a multimycotoxin UFLC-MS/MS method. J Pharm Pharmacol. 2019;71(7):1172-83. doi: 10.1111/jphp.13101, PMID 31037735.
34. Derangula VR, Pilli NR, Nadavala SK, Adireddy V, Inamadugu JK, Ponneri V. Liquidchromatography–tandem mass spectrometric assay for the determination of tetrabenazine and its active metabolites in human plasma: a pharmacokinetic study. Biomed Chromatogr. 2013;27(6):792-801. doi: 10.1002/bmc.2862, PMID 23339053.
35. Zhong D, Shi X, Sun L, Chen X. Determination of three major components of bitespiramycin and their major active metabolites in rat plasma by liquid chromatography-ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791(1-2):45-53. doi: 10.1016/s1570-0232(03)00205-8, PMID 12798164.